Drugs / rhPro-UK
rhPro-UK
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT07617870 | Jun 2026 → Dec 2027 expected | ischemic stroke | The First Affiliated Hospital of Zhengzhou University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07389460 | Apr 2026 → Dec 2027 expected | ischemic stroke | First Affiliated Hospital Xi'an Jiaotong University | Recruiting | No outcome recorded |
| Phase 3 | NCT05700591 | Jan 2023 → Mar 2024 | ischemic stroke | Tasly Biopharmaceuticals Co., Ltd. | Completed | Met primary |
| Phase 3 | NCT05507645 | Nov 2022 → Mar 2024 | ischemic stroke, thrombotic disease | Beijing Tiantan Hospital | Completed | Missed primary |
| Phase 3 | NCT02367976 | Jan 2015 → Dec 2016 | ST-elevation myocardial infarction | Suzhou RxD Biopharmaceutical Co., Ltd | Unknown | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rhPro-UK | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05700591 ↗ |
| Known as | recombinant human prourokinase | “Recombinant human prourokinase (rhPro-UK), a novel fibrin-specific thrombolytic agent independently developed in China” NCT07617870 ↗3“Recombinant human prourokinase (rhPro-UK) is a new generation of specific plasminogen activator” PMID 38296588 ↗ Dec 2024 “intravenous recombinant human Prourokinase (rhPro-UK) in acute ischemic stroke patients” NCT07389460 ↗ “Recombinant Human Pro-urokinase (rhPro-UK)” NCT05700591 ↗ |
| Known as | recombinant prourokinase | “Recombinant prourokinase (rhPro-UK) is a specific plasmin activator” PMID 38907679 ↗ Aug 2024 |
| Action | Activate | “specific plasminogen activator” PMID 38296588 ↗ Dec 2024 |
| Modality | Protein / enzyme biologic | “Recombinant human prourokinase (rhPro-UK) is a new generation of specific plasminogen activator” PMID 38296588 ↗ Dec 2024 |
| Route | Intravenous | “receive intravenous rhPro-UK (35 mg)” PMID 38296588 ↗ Dec 2024 |